These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 28885074

  • 1. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
    Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
    [Abstract] [Full Text] [Related]

  • 2. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ.
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [Abstract] [Full Text] [Related]

  • 3. Hyperforin in St. John's wort drug interactions.
    Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V.
    Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
    [Abstract] [Full Text] [Related]

  • 4. Drug interactions with St John's wort : mechanisms and clinical implications.
    Mannel M.
    Drug Saf; 2004 Mar; 27(11):773-97. PubMed ID: 15350151
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interactions of drugs with St John's wort.
    Zhou S, Chan E, Pan SQ, Huang M, Lee EJ.
    J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
    [Abstract] [Full Text] [Related]

  • 6. Clinical drugs that interact with St. John's wort and implication in drug development.
    Di YM, Li CG, Xue CC, Zhou SF.
    Curr Pharm Des; 2008 Jun; 14(17):1723-42. PubMed ID: 18673195
    [Abstract] [Full Text] [Related]

  • 7. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
    Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B.
    Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
    [Abstract] [Full Text] [Related]

  • 8. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
    Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R.
    Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
    [Abstract] [Full Text] [Related]

  • 9. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
    Wang EJ, Barecki-Roach M, Johnson WW.
    J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
    [Abstract] [Full Text] [Related]

  • 10. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
    Markowitz JS, DeVane CL.
    Psychopharmacol Bull; 2001 Jan; 35(1):53-64. PubMed ID: 12397870
    [Abstract] [Full Text] [Related]

  • 11. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J, Boddy AV, McLachlan AJ.
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [Abstract] [Full Text] [Related]

  • 12. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B.
    Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
    [Abstract] [Full Text] [Related]

  • 13. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [Abstract] [Full Text] [Related]

  • 14. Co-administration of St. John's wort and hormonal contraceptives: a systematic review.
    Berry-Bibee EN, Kim MJ, Tepper NK, Riley HE, Curtis KM.
    Contraception; 2016 Dec; 94(6):668-677. PubMed ID: 27444983
    [Abstract] [Full Text] [Related]

  • 15. An update on the ability of St. John's wort to affect the metabolism of other drugs.
    Rahimi R, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):691-708. PubMed ID: 22606944
    [Abstract] [Full Text] [Related]

  • 16. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
    Onoue S, Seto Y, Ochi M, Inoue R, Ito H, Hatano T, Yamada S.
    Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
    [Abstract] [Full Text] [Related]

  • 17. Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions.
    Galeotti N.
    J Ethnopharmacol; 2017 Mar 22; 200():136-146. PubMed ID: 28216196
    [Abstract] [Full Text] [Related]

  • 18. St John's wort, a herbal antidepressant, activates the steroid X receptor.
    Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK.
    J Endocrinol; 2000 Sep 22; 166(3):R11-6. PubMed ID: 10974665
    [Abstract] [Full Text] [Related]

  • 19. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
    Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L.
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug 22; 375(6):377-82. PubMed ID: 17593354
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of St. John's wort drug interactions revisited.
    Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE.
    Br J Pharmacol; 2020 Mar 22; 177(6):1212-1226. PubMed ID: 31742659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.